Press Releases

    Print Page  Close Window
BioMed Realty Trust Enters Into Leases Totaling 135,000 Square Feet of Space

- Agrees to Acquire San Diego Property for $23.3 Million -

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has signed three new leases totaling 135,000 square feet, including a 73,347 square-foot lease assumption with sanofi-aventis at its 270 Albany Street property in Cambridge, Massachusetts, and two leases for space that was previously subject to a master lease at its Bayshore Boulevard property in Brisbane, California. At the Bayshore property, the full building previously subject to the master lease has been re-leased with a 46,034 square-foot lease signed with XDx (Expression Diagnostics, Inc.), and a 15,410 square-foot lease amendment signed with InterMune Pharmaceuticals, Inc.

The triple-net lease with sanofi-aventis replaces, and extends by five years to 2018, the existing lease with Millennium Pharmaceuticals at the Albany Street property. The rent payments made by sanofi-aventis will be equal to those previously received from Millennium through the existing lease expiration in 2013, with annual increases for each year of the new five-year extension. Sanofi-aventis, one of the world's largest pharmaceutical companies with operations in over 100 countries, markets major pharmaceutical products derived from its research and a wide range of medicines adapted to local needs throughout the world.

The 61,444 square feet of new leases signed at the Bayshore property was previously under a master lease with Gal-Brisbane, the original seller of the property, which expired in February 2006. XDx, a private molecular diagnostics company focused on developing and commercializing practical applications built on insights from the Human Genome Project, has signed a seven-year, triple-net lease for 46,034 square feet that commences in November 2006. InterMune, a public company focused on developing and commercializing innovative therapies in pulmonology and hepatology, is an existing tenant at the Bayshore property and will lease the remaining 15,410 square feet of the building.

Separately, BioMed announced it has entered into an agreement to acquire 10835 Road to the Cure in San Diego, California, for approximately $23.3 million, including the assumption of approximately $15.8 million of debt. The property consists of a 64,800 square-foot two-story laboratory facility. The acquisition is currently scheduled to close in the third quarter of 2006.

"We are excited to enter into this new, long-term lease with sanofi-aventis, one of the largest and strongest companies in the pharmaceutical industry. We also are very pleased to have re-leased the space previously covered by a master lease at Bayshore. These transactions highlight both the strength of the Cambridge and San Francisco Bay Area life science markets as well as our continued ability to attract high-quality tenants to our properties," said Alan D. Gold, President and Chief Executive Officer of BioMed Realty Trust. "The Road to the Cure property, located in the premier Torrey Pines submarket of San Diego, also will be an excellent addition to our portfolio."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(TM). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry, and its properties and primary acquisition targets are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. BioMed's real estate portfolio consists of 43 properties, representing 64 buildings with approximately 4.8 million rentable square feet in each of the major life science markets in the United States. Additional information is available at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.
CONTACT: Kent Griffin, Chief Financial Officer of BioMed Realty Trust, Inc., +1-858-485-9840
Web site:

05/08/2006 12:48 EDT